Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience Grows

Rita Rubin

doi:10.1001/jama.2025.14180

August 22, 2025JAMA

Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience Grows

View at Publisher

Ask AI

Bookmark

Share

Key Points

Lecanemab and donanemab show effectiveness in treating mild cognitive impairment and early Alzheimer disease, suggesting promising results outside clinical trials.
The discussion includes findings on safety and overall patient experiences, indicating major advancements in Alzheimer disease management.
Assessments were made on the real-world use of antiamyloid therapies in clinical settings, emphasizing their role in improving patient outcomes and care.
These therapies may provide essential benefits beyond the trial environments, yet further corroboration through extensive studies may be necessary.

Implication

Medical News reveals real-world effectiveness and safety of lecanemab and donanemab for early Alzheimer disease, highlighting implications beyond clinical trials.

Abstract

This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rita Rubin (2025) studied this question.

synapsesocial.com/papers/68af5407ad7bf08b1eadaf55 https://doi.org/10.1001/jama.2025.14180

View at Publisher

Ask AI

Bookmark

Share

Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience Grows

Key Points

Implication

Abstract

Discussion

Cite This Study

Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience Grows

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading